Altria Q3 earnings and raised guidance not enough to change WAIT thesis

What happened

Altria reported third-quarter profit of $2.52 billion, up from $2.38 billion a year earlier, and raised its full-year earnings outlook, signaling continued resilience in its core cigarette business. The previous DeepValue master report had rated the stock WAIT at $69.50, citing rising discount cigarette share and declining on! pouch share as key risks to the thesis. While the Q3 beat is positive, the brief news release does not confirm whether pricing fully offset volume declines or whether smoke-free share improved, which were the main catalysts for a rating upgrade. The raised guidance suggests management sees better earnings visibility, but without segment-level detail we cannot yet rule out continued mix pressure. Investors should treat the news as modestly supportive but insufficient to change the WAIT rating until the full 10-Q is analyzed.

Implication

The Q3 results, while headline positive, omit the critical segment data that the prior DeepValue report identified as key: discount cigarette share and on! pouch share trends. Until those are disclosed in the 10-Q, investors should remain cautious about buying at current levels, especially with the stock already at 14.7x earnings. The raised full-year guidance does reduce the risk of an earnings disappointment and supports the dividend, but it does not address the competitive threats from ZYN and consumer trade-down. A better entry point may emerge if the stock pulls back to the $63 attractive entry level identified in the master report, or if the next filing confirms improving mix and smoke-free share. For now, existing holders can continue to collect the dividend, while new money should wait for more clarity.

Thesis delta

The Q3 earnings beat and raised guidance modestly improves near-term earnings visibility and supports the dividend safety case. However, it does not resolve the structural concerns around discount cigarette share and on! pouch share that underpinned the WAIT rating. Therefore, the WAIT thesis is maintained pending confirmation that pricing is offsetting volume declines and smoke-free products are gaining traction.